Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Build A Bear Workshop Inc (BBW) vs Cytokinetics Inc (CYTK) Price & Performance

Build A Bear Workshop IncTrade
Cytokinetics IncTrade

Price performance (Past 24H)

Key statistics

Build A Bear Workshop Inc vs Cytokinetics Inc — how do they compare? Build A Bear Workshop Inc trades at $36.09 (market cap $461.88M), while Cytokinetics Inc trades at $76.22 (market cap $10.63B). The key difference: Cytokinetics Inc is far larger — about 23× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.5% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

BBWCYTK
Market Cap
$461.88M$10.63B
Sector
Consumer CyclicalTechnology
52-Week High
$75.85$87.26
52-Week Low
$29.84$34.31
Enterprise Value
$561.32M$10.74B
Dividend Yield
2.5%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Build A Bear Workshop Inc

Build-A-Bear Workshop (BBW) trades at $36.09, down 3.14% today, but maintains strong fundamentals with a P/E of 8.63 and robust profitability metrics including 35.87% ROE. The stock shows technical bullish signals with moving averages supporting upward momentum, though RSI levels suggest potential near-term overbought conditions. Recent earnings beats and strategic product launches position the company for continued growth despite current price weakness.

BBW presents compelling value with analyst consensus price target of $62.50 representing 73% upside potential. The debt-free balance sheet, consistent dividend payments, and international expansion strategy support long-term growth, though near-term consumer spending pressures and competitive retail environment pose execution risks for investors.

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

Returns comparison

Trailing returns across standard periods

About Build A Bear Workshop Inc

Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.

Read more on BBW

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK